Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. The Food and Drug Administration faces an escalating shortage of cancer drugs with limited authority to address the crisis. At least 14 cancer drugs are in critically short supply across the U.S. right now. The shortage is putting patient's lives at risk and forcing some hospitals to ration the medication. Hospitals across the U.S. told CNBC shortages of cisplatin and carboplatin are particularly concerning because they are so widely used for so many different types of cancer. The FDA doesn't have the power to force companies to increase production or change distribution. But the agency is allowing the temporary importation of unapproved cancer drugs from overseas to ease the shortage. The FDA has authorized a Chinese manufacturer to ship unapproved cisplatin into the U.S. It's unclear whether these temporary imports can meet patient demand. Feel free to send any tips, suggestions, story ideas and data to me at spencer.kimball@nbcuni.com. |
|
|
The Food and Drug Administration has authorized the temporary importation of an unapproved chemotherapy drug from China in an effort to ease an acute shortage of cancer drugs in the United States, according to an update posted to the agency's website on Friday. Qilu Pharmaceutical, which makes and markets cisplatin injections in China, received FDA permission to export that drug to the U.S. market weeks ago, a document shows. The cancer drug shortages have forced some hospitals to ration medications by reducing the dosage to extend the supply and prioritizing patients who have a better chance of being cured. |
|
|
Medicare Part B will cover treatments for Alzheimer's disease that receive U.S. Food and Drug Administration approval, according to the federal agency that administers the program for seniors. Anyone who has Medicare Part B and meets "eligibility criteria" will be covered for new antibody treatments such as Leqembi once the FDA approves them, said Chiquita Brooks-LaSure, the administrator of the Centers for Medicare & Medicaid Services, on Thursday. |
|
|
The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes thousands of seniors every year. Pfizer, in a statement Wednesday, said it expects to have supply available in the third quarter of this year ahead of the RSV season. The Centers for Disease Control and Prevention's committee of independent advisors will meet on June 21 to make recommendations on the use of the vaccine. |
|
|
© 2023 CNBC LLC. All rights reserved. A property of NBCUniversal. 900 Sylvan Avenue, Englewood Cliffs, NJ 07632 Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis. Data also provided by THOMSON REUTERS |
|
|
|
If you believe this has been sent to you in error, please safely unsubscribe.
Tidak ada komentar:
Posting Komentar